Bicifadine
Alternative Names: CL 220075; DOV 220075Latest Information Update: 02 Mar 2009
At a glance
- Originator Wyeth
- Developer DOV Pharmaceutical; XTL Biopharmaceuticals
- Class Heterocyclic bicyclo compounds; Non-opioid analgesics; Small molecules
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic neuropathies; Osteoarthritis; Pain
Most Recent Events
- 18 Nov 2008 Top-line efficacy data from a phase IIb trial in Diabetic neuropathic pain released by XTL Biopharmaceuticals
- 09 Oct 2008 XTL Biopharmaceuticals completes a phase IIb trial in Diabetic neuropathies in US, Germany, Israel and India
- 30 Jun 2008 XTL completes randomisation in its phase IIb trial for diabetic neuropathic pain in the US, Germany, Israel & India